000065284 001__ 65284
000065284 005__ 20190709135645.0
000065284 0247_ $$2doi$$a10.3389/fimmu.2017.01803
000065284 0248_ $$2sideral$$a104263
000065284 037__ $$aART-2017-104263
000065284 041__ $$aeng
000065284 100__ $$0(orcid)0000-0001-8841-6593$$aGonzalo-Asensio, J.$$uUniversidad de Zaragoza
000065284 245__ $$aMTBVAC: Attenuating the human pathogen of tuberculosis (TB) toward a promising vaccine against the TB epidemic
000065284 260__ $$c2017
000065284 5060_ $$aAccess copy available to the general public$$fUnrestricted
000065284 5203_ $$aBacille Calmette-Guérin (BCG) is a live-attenuated strain of Mycobacterium bovis developed a century ago by repeated subculture. It remains the only vaccine against tuberculosis (TB) in use today, and it offers variable protection against the respiratory forms of TB responsible for transmission. The principal genetic basis for BCG attenuation is the loss of the region of difference 1 (RD1) that includes the genes codifying for production and export of the major virulence factor ESAT6. Today more than 13 TB vaccine candidates are in clinical evaluation. One of these candidates is MTBVAC, which is based on a rationally attenuated Mycobacterium tuberculosis clinical isolate belonging to modern lineage 4, one of the most widespread lineages among humans. MTBVAC conserves most of the T cell epitopes described for TB including the major immunodominant antigens ESAT6 and CFP10 of the RD1, deleted in BCG. After almost 20 years of discovery and preclinical development, MTBVAC is the only live attenuated vaccine based on a human pathogen that has successfully entered clinical trials as a preventive vaccine in newborns, aiming to replace BCG, and as a preventive vaccine in adolescents and adults (BCG-vaccinated at birth). Our recent preclinical studies have demonstrated that MTBVAC-induced immunity to ESAT6 and CFP10 correlate with improved efficacy relative to BCG encouraging exploration of these responses in human clinical trials as potential biomarkers and identification of these antigens as possible correlates of vaccine-induced protection. Such data would be extremely valuable as they would greatly accelerate clinical development to efficacy trials.
000065284 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020$$9info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020$$9info:eu-repo/grantAgreement/ES/DGA/FSE
000065284 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000065284 590__ $$a5.511$$b2017
000065284 591__ $$aIMMUNOLOGY$$b30 / 155 = 0.194$$c2017$$dQ1$$eT1
000065284 592__ $$a2.803$$b2017
000065284 593__ $$aImmunology and Allergy$$c2017$$dQ1
000065284 593__ $$aImmunology$$c2017$$dQ1
000065284 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000065284 700__ $$0(orcid)0000-0001-8644-120X$$aMarinova, D.$$uUniversidad de Zaragoza
000065284 700__ $$0(orcid)0000-0003-2993-5478$$aMartin, C.$$uUniversidad de Zaragoza
000065284 700__ $$0(orcid)0000-0001-7897-9173$$aAguilo, N.$$uUniversidad de Zaragoza
000065284 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000065284 7102_ $$11008$$2X$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cProy. investigación HQA
000065284 773__ $$g8 (2017), Art.1083 [8 pp]$$pFront. immunol.$$tFrontiers in Immunology$$x1664-3224
000065284 8564_ $$s203419$$uhttps://zaguan.unizar.es/record/65284/files/texto_completo.pdf$$yVersión publicada
000065284 8564_ $$s99220$$uhttps://zaguan.unizar.es/record/65284/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000065284 909CO $$ooai:zaguan.unizar.es:65284$$particulos$$pdriver
000065284 951__ $$a2019-07-09-12:40:37
000065284 980__ $$aARTICLE